Shopping Cart 0
Cart Subtotal
USD 0

Mundipharma International Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Mundipharma International Ltd (Mundipharma) engages in the research and development of products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers its products through its network of subsidiaries, independent associated companies, partners and joint ventures. The company's network includes Napp Pharmaceuticals, Norpharma and the Mundipharma independent associated companies. The company provides its services to patients, healthcare professionals and health systems worldwide. It has operations in Australia, Japan, New Zealand, Russia, Singapore, Philippines, South Africa, South Korea, Canada, China and USA. Mundipharma is headquartered in Cambridge, the UK.

Mundipharma International Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Mundipharma Acquires Rights to CAP7.1 from CellAct 17

Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 18

Purdue Pharma Acquires Rights to VM-902A from VM Pharma 19

Venture Financing 20

Kolltan Pharma Raises USD 60 Million In Series D Financing 20

Partnerships 22

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 22

Novartis and Mundipharma Enter into Agreement 23

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 24

Mundipharma Expands Agreement with Kolon Life Science 25

University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 26

University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 27

Mundipharma Enters into Distribution Agreement with Shionogi 28

Purdue Pharma to Form Joint Venture with AnaBios 29

Eisai Enters into Agreement with Purdue Pharma 30

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 31

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 32

ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 34

Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 35

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 37

Licensing Agreements 39

Mundipharma Enters into Licensing Agreement with Moberg Pharma 39

Mundipharma Enters into Licensing Agreement with Helsinn for ALOXI 40

Mundipharma Enters into Licensing Agreement with Neovii Pharma 41

Mundipharma Enters into Licensing Agreement with Starpharma Holding 42

Mundipharma Enters into Licensing Agreement with Endoceutics 43

Mundipharma Enters into Licensing Agreement with Grunenthal 44

Mundipharma Enters into Licensing Agreement with Paion 45

Mundipharma Expands Licensing Agreement with NTC 46

Mundipharma Enters into Licensing Agreement with APR Applied Pharma Research 47

Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 48

Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 49

Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 50

Mundipharma Enters into Licensing Agreement with Vectura for VR2076 51

Purdue Pharma Enters into Licensing Agreement with Exicure 52

Purdue Pharma Enters into Licensing agreement with AnaBios 53

Purdue Pharma Enters Into Licensing Agreement With Medical Developments 54

Mundipharma International Enters into Licensing Agreement with Orexo 55

Helsinn Signs Licensing Agreement with Purdue Pharma Canada 56

Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 57

Mundipharma International Enters into Licensing Agreement with Helsinn 58

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 59

SkyePharma Enters into Option Agreement with Mundipharma 60

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 61

Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 63

Mundipharma Enters into Licensing Agreement with Helsinn 64

Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 65

Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 66

Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 67

Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 69

Mundipharma Enters Into Licensing Agreement With Grunenthal 70

Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 71

Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 72

Mundipharma Enters Into Licensing Agreement With Shionogi 73

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 74

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 75

Asset Transactions 76

Fidelio Healthcare Partners to Acquire Production Site and Facilities from Mundipharma 76

Acquisition 77

Purdue Pharma to Acquire SpineThera 77

Mundipharma Acquires 100% Stake in Cinfa Biotech from Infarco 78

Mundipharma Acquires Tolmar Australia 79

Mundipharma International Ltd-Key Competitors 80

Mundipharma International Ltd-Key Employees 81

Mundipharma International Ltd-Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Joint Venture 85

Recent Developments 86

Corporate Communications 86

Dec 13, 2017: Dr Alberto Martinez appointed President and CEO of Mundipharma International 86

Dec 05, 2017: Mundipharma names Philippe Mazas as Chief Information Officer 87

Appendix 88

Methodology 88

About GlobalData 88

Contact Us 88

Disclaimer 88


List Of Figure

List of Figures

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Mundipharma International Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Mundipharma Acquires Rights to CAP7.1 from CellAct 17

Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 18

Purdue Pharma Acquires Rights to VM-902A from VM Pharma 19

Kolltan Pharma Raises USD 60 Million In Series D Financing 20

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 22

Novartis and Mundipharma Enter into Agreement 23

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 24

Mundipharma Expands Agreement with Kolon Life Science 25

University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 26

University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 27

Mundipharma Enters into Distribution Agreement with Shionogi 28

Purdue Pharma to Form Joint Venture with AnaBios 29

Eisai Enters into Agreement with Purdue Pharma 30

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 31

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 32

ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 34

Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 35

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 37

Mundipharma Enters into Licensing Agreement with Moberg Pharma 39

Mundipharma Enters into Licensing Agreement with Helsinn for ALOXI 40

Mundipharma Enters into Licensing Agreement with Neovii Pharma 41

Mundipharma Enters into Licensing Agreement with Starpharma Holding 42

Mundipharma Enters into Licensing Agreement with Endoceutics 43

Mundipharma Enters into Licensing Agreement with Grunenthal 44

Mundipharma Enters into Licensing Agreement with Paion 45

Mundipharma Expands Licensing Agreement with NTC 46

Mundipharma Enters into Licensing Agreement with APR Applied Pharma Research 47

Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 48

Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 49

Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 50

Mundipharma Enters into Licensing Agreement with Vectura for VR2076 51

Purdue Pharma Enters into Licensing Agreement with Exicure 52

Purdue Pharma Enters into Licensing agreement with AnaBios 53

Purdue Pharma Enters Into Licensing Agreement With Medical Developments 54

Mundipharma International Enters into Licensing Agreement with Orexo 55

Helsinn Signs Licensing Agreement with Purdue Pharma Canada 56

Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 57

Mundipharma International Enters into Licensing Agreement with Helsinn 58

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 59

SkyePharma Enters into Option Agreement with Mundipharma 60

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 61

Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 63

Mundipharma Enters into Licensing Agreement with Helsinn 64

Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 65

Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 66

Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 67

Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 69

Mundipharma Enters Into Licensing Agreement With Grunenthal 70

Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 71

Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 72

Mundipharma Enters Into Licensing Agreement With Shionogi 73

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 74

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 75

Fidelio Healthcare Partners to Acquire Production Site and Facilities from Mundipharma 76

Purdue Pharma to Acquire SpineThera 77

Mundipharma Acquires 100% Stake in Cinfa Biotech from Infarco 78

Mundipharma Acquires Tolmar Australia 79

Mundipharma International Ltd, Key Competitors 80

Mundipharma International Ltd, Key Employees 81

Mundipharma International Ltd, Subsidiaries 82

Mundipharma International Ltd, Joint Venture 85

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

Mundipharma International Ltd (Mundipharma) engages in the research and development of products for the treatment pain management, respiratory, cancer and inflammatory conditions. The company commercializes and launches products within Europe and rest of the world. Mundipharma offers its products through its network of subsidiaries, independent associated companies, partners and joint ventures. The company's network includes Napp Pharmaceuticals, Norpharma and the Mundipharma independent associated companies. The company provides its services to patients, healthcare professionals and health systems worldwide. It has operations in Australia, Japan, New Zealand, Russia, Singapore, Philippines, South Africa, South Korea, Canada, China and USA. Mundipharma is headquartered in Cambridge, the UK.

Mundipharma International Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Mundipharma Acquires Rights to CAP7.1 from CellAct 17

Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 18

Purdue Pharma Acquires Rights to VM-902A from VM Pharma 19

Venture Financing 20

Kolltan Pharma Raises USD 60 Million In Series D Financing 20

Partnerships 22

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 22

Novartis and Mundipharma Enter into Agreement 23

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 24

Mundipharma Expands Agreement with Kolon Life Science 25

University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 26

University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 27

Mundipharma Enters into Distribution Agreement with Shionogi 28

Purdue Pharma to Form Joint Venture with AnaBios 29

Eisai Enters into Agreement with Purdue Pharma 30

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 31

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 32

ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 34

Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 35

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 37

Licensing Agreements 39

Mundipharma Enters into Licensing Agreement with Moberg Pharma 39

Mundipharma Enters into Licensing Agreement with Helsinn for ALOXI 40

Mundipharma Enters into Licensing Agreement with Neovii Pharma 41

Mundipharma Enters into Licensing Agreement with Starpharma Holding 42

Mundipharma Enters into Licensing Agreement with Endoceutics 43

Mundipharma Enters into Licensing Agreement with Grunenthal 44

Mundipharma Enters into Licensing Agreement with Paion 45

Mundipharma Expands Licensing Agreement with NTC 46

Mundipharma Enters into Licensing Agreement with APR Applied Pharma Research 47

Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 48

Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 49

Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 50

Mundipharma Enters into Licensing Agreement with Vectura for VR2076 51

Purdue Pharma Enters into Licensing Agreement with Exicure 52

Purdue Pharma Enters into Licensing agreement with AnaBios 53

Purdue Pharma Enters Into Licensing Agreement With Medical Developments 54

Mundipharma International Enters into Licensing Agreement with Orexo 55

Helsinn Signs Licensing Agreement with Purdue Pharma Canada 56

Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 57

Mundipharma International Enters into Licensing Agreement with Helsinn 58

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 59

SkyePharma Enters into Option Agreement with Mundipharma 60

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 61

Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 63

Mundipharma Enters into Licensing Agreement with Helsinn 64

Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 65

Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 66

Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 67

Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 69

Mundipharma Enters Into Licensing Agreement With Grunenthal 70

Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 71

Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 72

Mundipharma Enters Into Licensing Agreement With Shionogi 73

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 74

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 75

Asset Transactions 76

Fidelio Healthcare Partners to Acquire Production Site and Facilities from Mundipharma 76

Acquisition 77

Purdue Pharma to Acquire SpineThera 77

Mundipharma Acquires 100% Stake in Cinfa Biotech from Infarco 78

Mundipharma Acquires Tolmar Australia 79

Mundipharma International Ltd-Key Competitors 80

Mundipharma International Ltd-Key Employees 81

Mundipharma International Ltd-Locations And Subsidiaries 82

Head Office 82

Other Locations & Subsidiaries 82

Joint Venture 85

Recent Developments 86

Corporate Communications 86

Dec 13, 2017: Dr Alberto Martinez appointed President and CEO of Mundipharma International 86

Dec 05, 2017: Mundipharma names Philippe Mazas as Chief Information Officer 87

Appendix 88

Methodology 88

About GlobalData 88

Contact Us 88

Disclaimer 88


List Of Figure

List of Figures

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Mundipharma International Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Mundipharma International Ltd, Deals By Therapy Area, 2012 to YTD 2018 10

Mundipharma International Ltd, Medical Devices Deals, 2012 to YTD 2018 12

Mundipharma International Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Mundipharma Acquires Rights to CAP7.1 from CellAct 17

Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 18

Purdue Pharma Acquires Rights to VM-902A from VM Pharma 19

Kolltan Pharma Raises USD 60 Million In Series D Financing 20

Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 22

Novartis and Mundipharma Enter into Agreement 23

Janssen Pharmaceutica Enters into Distribution Agreement with Mundipharma Medical 24

Mundipharma Expands Agreement with Kolon Life Science 25

University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 26

University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 27

Mundipharma Enters into Distribution Agreement with Shionogi 28

Purdue Pharma to Form Joint Venture with AnaBios 29

Eisai Enters into Agreement with Purdue Pharma 30

Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 31

Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 32

ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 34

Mundipharma International Enters Into Co-Development Agreement With Northlake International For NL-101 35

Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 37

Mundipharma Enters into Licensing Agreement with Moberg Pharma 39

Mundipharma Enters into Licensing Agreement with Helsinn for ALOXI 40

Mundipharma Enters into Licensing Agreement with Neovii Pharma 41

Mundipharma Enters into Licensing Agreement with Starpharma Holding 42

Mundipharma Enters into Licensing Agreement with Endoceutics 43

Mundipharma Enters into Licensing Agreement with Grunenthal 44

Mundipharma Enters into Licensing Agreement with Paion 45

Mundipharma Expands Licensing Agreement with NTC 46

Mundipharma Enters into Licensing Agreement with APR Applied Pharma Research 47

Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 48

Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 49

Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 50

Mundipharma Enters into Licensing Agreement with Vectura for VR2076 51

Purdue Pharma Enters into Licensing Agreement with Exicure 52

Purdue Pharma Enters into Licensing agreement with AnaBios 53

Purdue Pharma Enters Into Licensing Agreement With Medical Developments 54

Mundipharma International Enters into Licensing Agreement with Orexo 55

Helsinn Signs Licensing Agreement with Purdue Pharma Canada 56

Mundipharma Enters into Licensing Agreement with Specialized Therapeutics 57

Mundipharma International Enters into Licensing Agreement with Helsinn 58

Mundipharma Enters into Licensing Agreement with SkyePharma and Sanofi for Flutiform 59

SkyePharma Enters into Option Agreement with Mundipharma 60

Mundipharma Enters into Licensing Agreement with Spectrum Pharma for Zevalin 61

Mundipharma Enters into Licensing Agreement with Medical Developments for Penthrox 63

Mundipharma Enters into Licensing Agreement with Helsinn 64

Helsinn Enters into Licensing Agreement with Mundipharma for Anamorelin 65

Helsinn Enters into Licensing Agreement with Mundipharma for NEPA 66

Mundipharma Enters into Licensing Agreement with Celltrion Healthcare Hungary for Remsima 67

Mundipharma Enters into Licensing Agreement with Genewel for Medifoam 69

Mundipharma Enters Into Licensing Agreement With Grunenthal 70

Helsinn Enters Into Licensing Agreement With Mundipharma For Netupitant-Palonosetron Fixed Dose Combination 71

Mundipharma Plans to Extend Licensing Agreement with Genewel for Medifoam 72

Mundipharma Enters Into Licensing Agreement With Shionogi 73

Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 74

Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 75

Fidelio Healthcare Partners to Acquire Production Site and Facilities from Mundipharma 76

Purdue Pharma to Acquire SpineThera 77

Mundipharma Acquires 100% Stake in Cinfa Biotech from Infarco 78

Mundipharma Acquires Tolmar Australia 79

Mundipharma International Ltd, Key Competitors 80

Mundipharma International Ltd, Key Employees 81

Mundipharma International Ltd, Subsidiaries 82

Mundipharma International Ltd, Joint Venture 85

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS